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ABSTRACT: 
Elevated levels of miR-21 expression are associated with many cancers, suggesting it may be a 
promising clinical biomarker. In prostate cancer (PCa), however, there is still no consensus about the 
usefulness of miR-21 as an indicator of disease progression. This systematic review and meta-
analysis was conducted to investigate the value of miR-21 expression as a prognostic measurement 
in PCa patients. Medline (Ovid), EMBASE, Web of Science, Scopus and Cochrane Library databases 
were systematically searched for relevant publications between 2010 to 2021. Studies exploring the 
relationship between miR-21 expression, PCa prognosis and clinicopathological factors were 
selected for review. Those reporting hazard ratio (HR) and 95% confidence intervals (CIs) were 
subject to meta-analyses. Fixed-effect models were employed to calculated pooled HRs and 95% CIs. 
Risk of bias in each study was assessed using QUIPS tool. Certainty of evidence in each meta-analysis 
was assessed using GRADE guidelines. A total of 64 studies were included in the systematic review. 
Of these, 11 were eligible for inclusion in meta-analysis. Meta-analyses revealed that high miR-21 
expression was associated with poor prognosis: HR=1.58 (95% CI=1.19-2.09) for biochemical 
recurrence, MODERATE certainty; HR=1.46 (95% CI=1.06-2.01) for death, VERY LOW certainty; and 
HR=1.26 (95% CI=0.70-2.27) for disease progression, VERY LOW certainty. Qualitative summary 
revealed elevated miR-21 expression was significantly positively associated with PCa stage, Gleason 
score and risk groups. This systematic review and meta-analysis suggests that elevated levels of miR-
21 are associated with poor prognosis in PCa patients. miR-21 expression may therefore be a useful 
prognostic biomarker in this disease.  
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INTRODUCTION: 
Prostate cancer (PCa) is the most commonly diagnosed cancer for males in 105 countries including 
North and South America, Western Europe and Australia 1. The majority of PCa cases are localised 
disease with very high survival rate after initial treatment (~100% 5-year survival), but recurrence 
may occur in about 40% as biochemical recurrence (BCR) or distant metastasis that has a 
significantly poorer prognosis (~30% 5-year survival) 2. Additionally, some may progress as 
castration-resistant prostate cancer (CRPC) or develop chemoresistance 3. 
Currently, prognosis is predicted by considering cancer stage, Gleason score, prostate-specific 
antigen (PSA) level, patient’s health condition, treatment choice and treatment response 4. However, 
these clinicopathological factors still have certain limitations. For example, Gleason score is a 
histological method which is subject to inter-observer variability, and clinicians can find the grading 
system confusing 5, 6. Staging may vary between clinical and pathological estimation, forcing 
clinicians to alter treatment regime, and prognosis for lower stage cancer is less than predictable 7. 
PSA lacks specificity and BCR, defined by rise in PSA level, does not necessarily predict clinical 
recurrence or metastasis with sufficient accuracy 8. Therefore, there is still a clear clinical need for 
novel molecular markers that may overcome some of these limitations 9. 
MicroRNAs (miRNAs) are a class of non-coding molecules which have emerged as strong candidates 
for useful clinical biomarkers 10. Over the past decade, they have been actively researched in a wide 
range of diseases, including prostate cancer 11, 12. miRNAs are estimated to regulate 60% of gene 
expression in human and some specifically target oncogenes or tumour suppressor genes 10, 11. The 
aberrant expression of miRNAs can therefore contribute to cancer development and several 
dysregulated miRNAs have been associated with PCa progression 12, 13. Importantly, miRNAs can be 
detected in blood and urine, as well as tissue. Indeed, they are known to be more stable in biofluids 
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However, more research is needed to understand which miRNAs are most relevant in prostate 
cancer.  
miR-21 is one of the most studied miRNAs and there is a large body of evidence to suggest that it has 
a predominantly oncogenic function since it is over-expressed in many cancers 14. As one of the first 
miRNAs to be categorized as an ‘oncomiR’, it has been subsequently evaluated for its potential use 
as a clinical biomarker in various cancers 15, 16, 17. Several recent systematic reviews have found 
evidence that circulating miR-21 levels can predict poor prognosis in oesophageal, pancreatic, 
colorectal and breast cancers 18, 19. In urological cancers, including PCa, Chen et al. found some 
evidence that miR-21 over-expression was significantly associated with unfavourable prognosis in 
their integrated analysis 20. However, despite evidence that it can contribute to PCa development, no 
systematic review or meta-analysis to date has been carried out specifically for miR-21 in this 
setting. Therefore, the purpose of this paper is to systematically evaluate studies related to 
prognostic value of miR-21 in PCa, appraising study qualities and synthesising evidence by meta-
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MATERIALS & METHODS: 
Protocol and registration 
This review was conducted following a protocol which was registered with the International 
Prospective Register of Systematic Reviews (PROSPERO; https://www.crd.york.ac.uk/prospero/) 
under the registration ID: CRD42020183408 on 23rd June 2020. The protocol was developed 
following guidance on PRISMA-P 21, systematic review and meta-analysis of prognostic factor studies 
22 and the checklist of items recommended in the PRISMA statement 23. 
Search Strategy 
Electronic databases from which records were retrieved include Medline (Ovid), EMBASE, Web of 
Science, Scopus and Cochrane Library, covering publications from 2010 to 2021 and they were last 
searched on 8th November 2021. Additionally, reference lists of included studies and relevant review 
papers were searched manually. Prognostic factor studies were prone to selective reporting in that 
miRNAs with insignificant findings might not be reported 24, therefore a high-sensitivity approach 
was used in the search strategy as shown in Supplementary Table ST 1.  Key words related to 
miRNAs, in addition to miR-21, were included to broaden the search to cover relevant studies that 
measured miR-21 but did not report the result. Retrieved records from databases were exported to 
systematic review manager Rayyan where duplicates were removed 25. Titles and abstracts of 
remaining records were screened for relevance independently by two reviewers. Full text of studies 
selected for inclusion were subsequently imported into another systematic review manager 
Covidence (www.covidence.org) where studies were assessed for eligibility in duplicate. Any 
disagreements were resolved through discussion.  
Eligibility criteria 
For inclusion in the systematic review, original peer-reviewed human studies published in English 
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included. In vitro, in silico and in vivo studies that did not include human participants were excluded. 
Studies without original human data which analysed publicly available human data (e.g., from The 
Cancer Genome Atlas repository) were not included to avoid multiple counting of sample size. 
Review-type studies and duplicate reports were excluded for the same reason. If the same study was 
published in multiple journals, only the most informative or the most recent one was included. 
Studies published before 2010 were excluded due to advances in miRNA technology.  
For meta-analyses, studies with characteristics specified by PICOT (Table 1) were eligible for 
inclusion in meta-analysis 22. Length of follow-up was not restricted to broaden the number of 
inclusions and increase the number of eligible studies. 
Data collection process  
A data extraction form adapted from CHARMS-PF checklist 22 was created within Covidence to 
capture information about each study, source of data, PICOT details, sample size, missing data, 
statistical analysis methods, survival outcome results and/or association analysis results 
(Supplementary Table ST 2). Data was extracted independently in duplicate into separate forms. 
Completed forms were compared, and conflicts were resolved through discussion. Authors of 12 
studies were contacted for missing data or clarifications (Supplementary Table ST 3). Only data 
relevant to prognosis were considered, therefore data related to diagnosis and healthy or benign 
prostatic hyperplasia (BPH) controls were disregarded. 
Risk of bias in individual studies 
Judgment was made independently in duplicate using the Quality in Prognostic Factor Studies 
(QUIPS) tool which assesses risk of bias as HIGH, MODERATE, LOW or UNCLEAR in six domains 
(Supplementary Table ST 4) 26. For domain 3 “Prognostic factor measurement”, methods accepted as 
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“Adjustment for covariates”, the core set of desired adjustment covariates was predefined as 
Gleason score/grade and pathological/clinical stage. 
Statistical Analysis 
The principal summary measure for meta-analysis was hazard ratio (HR), presented with 95% 
confidence interval (CI) and p-value. Kaplan Meier plot presented with log-rank p-value was also 
accepted. Eligible studies of similar design in terms of outcome and handling of miR-21 data were 
grouped into separate meta-analyses. For each meta-analysis effect estimates were pooled as HR 
(95% CI) based on fixed-effect inverse variance method in the review manager RevMan5.4 27. 
Statistical heterogeneity was assessed by visual inspection of the forest plot, chi-square (Chi2) test 
and I2 test (Chi2 p≤0.1 indicates significant heterogeneity; I2 <30% denotes low/unimportant 
heterogeneity, 30-60% moderate heterogeneity, 50-90% substantial heterogeneity, and 75-100% 
considerable heterogeneity). Impact on the robustness of analyses by the presence of an outlier and 
the inclusion of a study that introduced clinical heterogeneity was assessed by sensitivity analyses. 
For qualitative summary, association measure included but was not limited to correlation, fold 
change (FC) or mean difference. 
Certainty of evidence  
For each analysis the certainty of evidence was rated according to the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) guidelines 28. This review estimated the 
prognostic value of miR-21 in PCa as an exploratory study without direct association with clinical 
decision making, therefore, certainty was rated based on the non-contextualised setting as HIGH, 
MODERATE, LOW or VERY LOW certainty. Starting from HIGH certainty, evidence could be rated 
down in five domains: risk of bias, inconsistency, indirectness, imprecision and publication bias; or 
rated up in three domains: large effect, dose response and plausible confounding. Assessment of 
publication bias was not possible due to low number of studies eligible for each analysis, which 
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Study selection was as shown in the flow diagram (Figure 1). Up until 23rd July 2020, 4859 records 
were retrieved from database searching and a further 90 were identified from manual searching of 
reference lists of included studies and relevant reviews. After duplicates were removed (n=2800), 
record screening identified 76 eligible studies for full-text assessment. 13 full-text articles were 
ineligible due to lack of prognostic data (n=8), lack of miR-21 data (n=4) and lack of original human 
prognostic data (n=1) (Supplementary Table ST 5). The remaining 63 studies 29-77, 79-92 were included in 
the systematic review, with 10 eligible for meta-analysis. On 8th November 2021, an update 
screening for meta-analysis identified one more eligible study 78, bringing the total number of 
included studies to 64, with 11 eligible for meta-analysis. 
Study characteristics 
Characteristics of all 64 studies included in this systematic review are summarised in Supplementary 
Table ST 6. Each included study was assigned a Study ID composed of first author’s name and 
publication year. The PICOT eligibility criteria (Table 1) identified studies on PCa patient cohorts 
which could be stratified against measurable parameters and outcomes for inclusion in the meta-
analysis. A total of 11 studies, with study sizes ranging from 31 to 478 participants, encompassing 
1485 PCa patients total, were eligible for meta-analysis (Tables 2 & 3). Amankwah2013 31 indicated 
that the recurrent group was oversampled, no rationale was provided. Sharova2021 78 was clearly 
indicated as prospective; Zedan2017 85 and Zhao2019a 89were clearly indicated as retrospective 
studies. Cohort types were projected for the rest judging by the details contained. Thus, six studies 
appeared to be prospective (Guan2016 42; Leite2015 60; Lin2014 64; Lin2017 65; Sharova2021 78; 
Yang2016 84) and four were retrospective (Amankwah2013 31; Melbø-Jørgensen2014 68; Zedan2017 85; 
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For population “P”, two studies from the same research group (Lin2014 64 & Lin2017 65) included 
male patients diagnosed with CRPC that underwent docetaxel chemotherapy (a different set of 
patients was used for each study, therefore no double counting). Participants of Guan2016 42 and 
Sharova2021 78 received androgen deprivation therapy (ADT) and androgen receptor-targeted 
agents (ARTA) respectively; However, Sharova2021 78 only included metastatic castration-resistant 
prostate cancer (mCRPC) patients. The rest of the studies (n=7) included male PCa patients that 
underwent resection surgeries such as radical prostatectomy (RP) and/or regional lymph node 
dissection. Not all studies reported the age range of participants, but it is apparent from available 
information that they were all around middle to old age groups at baseline (≥ 40 years).  
For index prognostic factor “I”, Lin2014 64, Lin2017 65, Sharova2021 78 and Yang2016 84 measured 
circulating miR-21 in plasma, serum or peripheral blood mononuclear cell (PBMC) samples while the 
rest (n=7) measured tissue miR-21 in formalin-fixed paraffin-embedded (FFPE) tumour samples; 
Li2012 61 and Zedan2017 85 measured miR-21 level by in situ hybridisation (ISH) methods that are 
semi-quantitative, while the rest (n=9) used real-time quantitative polymerase chain reaction (RT-
qPCR) techniques that are highly sensitive and specific 93. 
For comparator prognostic factors “C”, the most frequently included ones were Gleason score/grade 
(GS/GG; n=10 except Lin2017 65), PSA (n=10 except Amankwah2013 31) and pathological/clinical stage 
(pT/cT; n=8 except Lin2014 64, Lin2017 65 and Sharova2021 78). These were followed by age (n=6), 
haemoglobin (n=3), surgical margin (n=3), lymph node metastasis (pN; n=2) and alkaline 
phosphatase (n=2). Body mass index (BMI), capsular invasion, visceral metastasis, perineural 
infiltration, tumour size, vascular infiltration, digital rectal examination (DRE), prostate volume, 
neutrophil/lymphocyte ratio and time to CRPC were each included once between 6 studies 
(Amankwah2013 31; Li2012 61; Lin2014 64; Melbø-Jørgensen2014 68; Sharova2021 78; Zhao2019a 89). 
For outcomes of interest “O”, Lin2014 64, Lin2017 65, Sharova2021 78 and Yang2016 84 observed for 
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and Sharova2021 78 observed for progression-free survival (PFS), defined as time to development of 
CRPC from initiation of ADT by Guan2016 42, and as time to radiological/clinical progression from 
initiation of ARTA by Sharova2021 78. The rest (n=6) observed for recurrence-free survival (RFS), 
generally defined as time from the date of treatment to the date of biochemical recurrence (BCR) 
with slight variations as indicated in Table 2 footnotes d, f and g. Latest follow-up times across 
studies ranged from 45 months (Lin2017 65) to 254 months (Amankwah2013 31), averaging up to 125 
months (~10 years). Not enough information was provided in Zedan2017 85 to estimate the follow-up 
period. 
Risk of bias within studies 
Risk of bias within each eligible study was assessed using the QUIPS tool 26; two independent 
judgments were made before reaching consensus. Final ratings of risk of bias within the 11 studies 
eligible for meta-analyses are summarised in Table 4. 
Overall, no eligible study achieved LOW risk of bias in all domains. Most concerns in risk of bias were 
around domain 5 and 6 mainly due to inadequate adjustment for predefined important prognostic 
factors and selective reporting. The lack of rationale for sample size appears to be a common 
problem across the majority of eligible studies. 
Meta-analyses & Sensitivity Analyses 
For all outcomes, results of each study eligible for meta-analyses are summarised in Table 5 (n=11). 
Six studies observed RFS, four observed OS, and two observed PFS. Effect estimates were pooled as 
HR (95% CI) based on fixed-effect inverse variance method. Statistical heterogeneity was determined 
by visual inspection of the forest plot, Chi2 test and I2 test (Chi2 p≤0.1 indicates significant 
heterogeneity; I2 <30% denotes low/unimportant heterogeneity, 30-60% moderate heterogeneity, 
50-90% substantial heterogeneity, and 75-100% considerable heterogeneity). 
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This analysis includes Amankwah2013 31, Leite2015 60, Leite2012 61 and Melbø-Jørgensen2014 68 as 
they have observed RFS as outcome and dichotomised tissue miR-21 expression data into high and 
low groups (median as cut-off for Amankwah2013 31, Leite2015 60 and Li2012 61; 4th quartile for 
Melbø-Jørgensen2014 68). Unadjusted and adjusted effect estimates of all four studies were 
combined in Analysis 1.1 (Figure 2a) and Analysis 1.2 (Figure 3a) respectively for comparison to 
examine the effect of heterogeneity caused by differences in covariate adjustment. Overall number 
of participants is 838 (364 with BCR; 474 without BCR). 
The overall effect of unadjusted estimates, as shown in the forest plot of Analysis 1.1, favours low 
miR-21, suggesting high miR-21 expression is associated with higher risk of BCR (HR=1.54, 95% 
CI=1.23-1.92). Statistical heterogeneity tests indicate significantly considerable heterogeneity (Chi2 
p<0.00001; I2=90%), most likely caused by the presence of an outlier (Amankwah2013 31) which 
showed an opposite direction of effect estimate to the other studies. To probe this further, the 
impact of the outlier on this meta-analysis was assessed by sensitivity analysis. Results of sensitivity 
analysis (Figure 2b) confirmed the data from Amankwah2013 31 as the source of statistical 
heterogeneity (I2=0% without outlier). However, the inclusion of the outlier did not change the effect 
estimate significantly, therefore the results of Analysis 1.1 are still valid. 
The overall effect of adjusted estimates (Analysis 1.2) is very close to that of unadjusted estimates 
(Analysis 1.1) supporting the same conclusion, i.e., it favours low miR-21, suggesting high miR-21 
expression is associated with higher risk of BCR (HR=1.58, 95% CI=1.19-2.09; Figure 3a). However, 
different from Analysis 1.1, Melbø-Jørgensen2014 68 now occupied over half of the overall weight 
(52.8%) with Li2012 61 weighing only 18.8%. Amankwah2013 31 still appears to be outlying, and 
statistical heterogeneity tests also indicate significantly substantial heterogeneity (Chi2 p=0.05; 
I2=62%). Again, sensitivity analysis repeating Analysis 1.2 without Amankwah2013 31 reduced 
statistical heterogeneity to insignificant and low/unimportant (I2=30%; Figure 3b), verifying the 
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reveals that the inclusion of the outlier has limited impact, and that the results of Analysis 1.2 are 
robust. 
Comparing the two analyses, covariate adjustment in Analysis 1.2 had brought Amankwah2013 31 
closer to the other studies with the upper CI arm crossing the line of no effect and overlapping with 
others’, that might explain the lower statistical heterogeneity indicated by I2 values compared to 
Analysis 1.1 (62% vs 90%). However, eliminating the effect of outlier, higher I2 value of adjusted 
estimates compared to unadjusted (30% vs 0%) implies that differences in covariate adjustment 
might have introduced some heterogeneity, though low and insignificant.  
Analysis 2: Recurrence-free survival; continuous miR-21 data (n=2) 
This analysis includes Zedan2017 85 and Zhao2019a 89 as both have observed RFS as outcome against 
continuous miR-21 expression in tissue samples. Only unadjusted effect estimates were combined in 
Analysis 2 (Figure 4) because of lack of multivariate analysis data for Zedan2017 85. Overall number 
of participants is 255 (117 with BCR; 138 without BCR). 
The overall effect estimate (HR=1.12, 95% CI=1.01-1.26) favours lower miR-21, indicating that higher 
miR-21 expression is associated with higher risk of BCR. The overall effect in the forest plot showed 
high precision from the tight CI and statistical heterogeneity is very low (Chi2 p=0.75; I2=0%). 
However, the data points are very close to the line of no effect with the lower CI of Zedan2017 85 
across. The overall weight is dominated by Zhao2019a 89 (96.2%) between only two studies. 
Analysis 3: Overall survival; dichotomous miR-21 data (n=4) 
This analysis included Lin2014 64, Lin2017 65, Sharova2021 78 and Yang2016 84 as they are similar in 
outcome observed (OS), handling of miR-21 data (dichotomised) and source of miR-21 (circulating 
samples). Only unadjusted effect estimates were combined in Analysis 3 (Figure 5a) because of lack 
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miR-21 data in multivariate analysis for Lin2017 65. Overall number of participants is 307 (163 dead; 
144 alive). 
The overall effect in Analysis 3 favours low miR-21, suggesting high miR-21 expression is associated 
with higher risk of death (HR=1.46, 95% CI=1.06-2.01; Figure 5a). Sharova2021 78 was outlying in the 
opposite direction to the rest and mostly likely have caused the considerable heterogeneity (Chi2 
p=0.0008; I2=82%); Therefore the impact of including Sharova2021 78 in Analysis 3 was examined in 
sensitivity analysis (Figure 5b).Sensitivity analysis repeating Analysis 3 without Sharova2021 78 
significantly reduced heterogeneity to low/unimportant level (Chi2 p=0.25; I2=27%; Figure 5b), 
confirming an outlier as the main source of heterogeneity, and that had brought the overall effect 
estimate closer to the line of no effect. 
Analysis 4: Progress-free survival; dichotomous miR-21 data (n=2) 
Analysis 4 included Guan2016 42 and Sharova2021 78 because both studies observed PFS as outcome. 
Overall number of participants is 116 (73 with progression; 43 without progression). Figures 6a and 
6b showed meta-analysis results along with forest plots of combined unadjusted and adjusted effect 
estimates respectively (Analyses 4.1 and 4.2). Neither analysis reached a significant overall effect (CIs 
crossing line of no effect), most likely since only two studies with opposite effect estimates were 
available, which also contributed to considerable heterogeneities (Chi2<0.1; I2>80%). Therefore, no 
meaningful conclusion could be drawn from Analysis 4. 
Qualitative Summary & Associations 
Most of the 64 studies included in this review compared the association of miR-21 with commonly 
used clinicopathological prognostic factors (Table 6). These included Gleason score/grade (n=28); 
pathological/clinical stage (n=18); serum PSA level (n=18); risk stratification (n=12); and age at 
diagnosis (n=9). Association of miR-21 expression with recurrence (n=19) and metastasis (n=14) 
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prostate volume (n=4), chem-response (n=3), digital rectal examination (DRE) result (n=3), ethnicity 
(n=2) and surgical margin (n=2). Other comparisons made include genitourinary radiotoxicity 
(Kopcalic2019 53), neuroendocrine-like vs Adeno PCa (Ostano2020 71), follow-up time, family history 
(Shen2012 79) and reclassification (Zhao2019b 90). 
Results were grouped according to statistical significance (p<0.05/p>0.05), association direction 
(positive/negative) and sample source (tissue/circulating). Association measures varied between 
studies, these include fold change (FC), mean difference and correlation, meaning it was impractical 
to summarise findings according to comparison methods. Therefore, findings were summarised 
according to association directions. When higher miR-21 expression was associated with higher 
degree/presence of the comparators it was indicated as positive; when it was associated with lower 
degree/absence of the comparators it was negative. 
Additional figures demonstrating association results can be found in Supplementary Figure SF 1a-g. 
Twelve out of 28 studies (43%) that compared miR-21 levels in different Gleason scores/grades 
found significant positive association of miR-21 levels from tissue and circulating samples. Twelve 
out of 18 studies (67%) that compared miR-21 levels in different pathological/clinical stages found 
significant positive association of miR-21 mostly from circulating samples as well as tissue. In 
contrast, only three studies reported significant positive association in circulating miR-21 and serum 
PSA. Seven out of 19 studies (37%) found significant positive association between tissue/circulating 
miR-21 and biochemical recurrence, defined generally as biochemical recurrence determined by rise 
in serum PSA≥0.2-0.4 ng/ml after treatment. Ten out of 14 studies (71%) that compared miR-21 
levels in samples of metastatic vs localised PCa patients found significant positive association 
between metastatic PCa and miR-21 mostly in circulating samples (n=8; tissue n=2). 11 out of 12 
studies (92%) that examined risk stratification reported positive association of higher risk with 
elevated miR-21 expression, although only 4 (33%) of these were found to be statistically significant.  
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Publication bias was not assessed due to low number of studies eligible for each analysis. No analysis 
was rated up for large effect, dose response or plausible confounding. Table 7 presented judgments 
of rate-downs and overall certainties of each analysis. Overall certainty is MODERATE for Analysis 
1.2; LOW for Analyses 1.1 and 2; VERY LOW for Analyses 3, 4.1 and 4.2. See Supplementary Table ST 
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DISCUSSION: 
In this report, we have performed the first systematic review and meta-analysis of miR-21 as a 
prognostic factor in PCa. miR-21 is one of the most studied miRNAs in cancer and has been shown to 
play a role in many different cellular mechanisms which can contribute to cancer progression, 
including PCa 95. Although miR-21 targets many genes and thus regulates many genetic pathways, it 
appears to act in a primarily oncogenic fashion with many studies reporting elevated levels in 
samples taken from cancer patients. Despite this body of evidence, there is still doubt about 
whether it may be a useful biomarker for cancer prognosis, so robust analyses of existing studies are 
needed to determine its value for clinical application and to inform the optimal design of future 
studies. 
The pooled results of all meta-analyses reported here supported an association between high miR-
21 expression and poor prognosis in PCa. Regarding RFS, Analysis 1.2 estimated a 58% increased risk 
of BCR for high baseline expression of tissue miR-21 (HR=1.58, 95% CI=1.19-2.09) with MODERATE 
certainty of evidence. For OS, Analysis 3 estimated a 75% increased risk of death for high baseline 
expression of circulating miR-21 with VERY LOW certainty of evidence (HR=1.75, 95% CI=1.26-2.45). 
No meaningful conclusion could be drawn for PFS in Analysis 4 due to considerable heterogeneity 
between only two eligible studies. The heterogeneity could be attributed to differences in 
population, miR-21 source and PFS definition. Guan2016 42 recruited pathologically confirmed PCa 
patients while Sharova2021 78 only included mCRPC patients; Guan2016 42 detected miR-21 from 
FFPE tissue samples while Sharova2021 78 examined it in plasma samples; Guan2016 42 defined PFS as 
time to development of CRPC while Sharova2021 78 defined it as time to radiological/clinical 
progression. Analysis 4 demonstrated the importance of only combining results of similar studies as 
a basic principle of meta-analysis. The limited certainty in OS result and lack of similar studies in PFS 
for a meaningful meta-analysis indicated that more high-quality prognostic studies are needed for 
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that miR-21 may have prognostic value in PCa. This data suggests miR-21 can be put forward as a 
strong candidate for the prognosis of the disease, although further work is clearly needed to prove 
its value more conclusively as a biomarker. 
Our results agreed with systematic reviews in other cancers such as non-small cell lung, pancreatic 
and colorectal cancers 96, 97, 98. These suggested high tissue miR-21 as an unfavourable prognostic 
biomarker. Circulating miR-21 overexpression was also associated with poor prognosis in digestive 
system and breast cancers 18, 19, 99. This is not unexpected, given that it is generally agreed to act as 
an oncogene, but this understanding of its functional role in the cell can only be translated into 
medical application when the literature available is subject to methodical evaluation in studies such 
as these. 
However, it is worth noting that the authors of the papers subject to meta-analysis here all indicated 
limitations with their studies. We recorded this as part of our data gathering process and further 
probed it through our quality assessment of individual studies. Pooled evidence by QUIPS and 
GRADE methodologies revealed sources of risk of bias and down-rate of certainty of evidence. In 
several studies, selective reporting and failure to adjust for the core set of covariates increased risk 
of bias and imprecision, thus decreased certainty of evidence. Furthermore, publication bias could 
not be properly assessed due to inadequate number of studies included in individual analysis. This 
was mainly due to high heterogeneity across studies, such as differences in outcome, handling of 
miR-21 data and sample source. The limited similarities meant that eligible studies had to be split 
into separate small analyses, therefore reducing the impact of meta-analyses. It was unfortunate 
that so few of the published studies met the required criteria for inclusion in meta-analysis, which 
limits the strength of the analyses and our subsequent ability to draw firm conclusions. Although the 
very nature of a properly conducted meta-analysis is to be robust and consistent in the application 
of the methodology, limitations in selected studies are inevitably reflected in the limitations of the 
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ideal. Perhaps that is to be expected since miRNAs as biomarkers is a relatively recent field of 
research, but it is clear that a lack of standardised approach to these type of biomarker studies 
makes it difficult to evaluate the clinical usefulness of miRNAs as prognostic biomarkers. Therefore, 
for any researchers carrying out future cancer prognostic studies of this type, it is highly 
recommended that they adhere to the Reporting Recommendations for Tumour Marker Prognostic 
Studies (REMARK) guidelines for proper study design, conduct, analysis and reporting 100. This will 
reduce risk of bias and heterogeneity across studies to generate higher quality evidence and more 
opportunity for comparison in meta-analyses like the ones presented here. Evidently, Zhao2019a 89 
was the only included study that followed the guidelines and achieved LOW risk of bias in most 
QUIPS domains. 
Although several of the full-text studies reviewed were not eligible for meta-analysis, they 
nevertheless contained useful data about the association of miR-21 with PCa, which is important to 
discuss since it can inform future study design.  Overall, several studies in this review supported the 
hypothesis that there is a significant positive association between miR-21 expression and various 
clinical measurements of PCa progression, such as stage, Gleason score, risk groups, metastasis and 
recurrence. Notably, very few studies found a significant association between miR-21 expression and 
serum PSA level or age at diagnosis. 
However, for clinical application of miR-21 analysis, several barriers must be overcome. A 
standardised method for measuring miR-21 must be decided upon. RT-qPCR, as used in many of the 
studies reported here, would seem the most appropriate technique at present in terms of sensitivity 
and applicability. Nevertheless, agreement is needed on common normalisation approaches and 
comparable internal controls, such as reference genes. Even with these measures in place, a 
consensus would then be needed on an appropriate cut-off value for prognostic outcome, which was 
very variable in the studies evaluated here. Another important consideration is that the correct miR-
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5p will be similar. The majority of the studies in this review did not specify miR-21 strand, which is 
also another reason to be cautious about the interpretation of the results presented here.  
Even if standardised approaches meant RT-qPCR was accepted as suitably sensitive and accurate 
method, the sample type in which to measure the miR-21 target is a further complication. Among 63 
studies included in this review, 31 measured miR-21 levels in circulating samples, including plasma, 
serum, PBMC, urine, exosome and whole blood; 30 measured miR-21 levels in tissue samples; 
Zedan2018 86 measured from both sample types; and Samaan2014 74 did not clearly state the sample 
source. Zedan2018 86 found significant correlation of miR-21 levels between matched tissue and 
plasma samples from 25 healthy patients (r=0.58, p<0.01) but not in 21 PCa patients (p=0.42). It is 
not certain that tissue and biofluid levels of miR-21 will be directly comparable, and it is also possible 
that different outcomes might be better predicted by miR-21 expression in one particular sample 
type. Thus, further inter- and intra-individual analyses would be needed to determine the relative 
value of these different sample types. It is therefore clear that for miR-21, or any other miRNA, to 
gain clinical acceptance as disease biomarker, it requires well-designed, prospective clinical studies 
to validate the findings reported here. Ideally, these studies should utilise the same PICOT criteria, 
ensuring common outcomes and measurements can then be compared between studies and across 
different research centres.  
Nevertheless, even though there are not yet enough well-designed studies to conclusively prove 
biomarker potential of miRNAs, it does appear increasingly likely that they will be used in future as 
non-invasive, liquid biomarkers for cancer and other diseases101, 102. With this in mind, miR-21 is a 
very attractive candidate to profile, since it is abundantly expressed in both tissue and biofluids, 
making it easy to measure 14, 103. In relation to PCa specifically, its involvement in promoting cancer 
growth, and related roles in important pathological changes, such as epithelial-to mesenchymal 
transition (EMT), is now well established 14, 104, so there is a strong biological rationale for measuring 
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often work synergistically as a regulatory network for gene expression, so the involvement of miR-21 
with other miRNAs should be considered. For instance, while this paper was being prepared, another 
systematic review and meta-analysis was published which reported the prognostic significance of 15 
microRNAs related to metastasis and EMT process in PCa patients 105. Surprisingly, miR-21 was not 
included among them, but the authors did acknowledge the link between their selected miRNAs and 
miR-21 in their discussion, and they concluded that a miRNA panel of biomarkers would be optimal 
to determine progression risk. Similarly, another recent paper used meta-analysis methods to 
identify miR-21 as one of several miRNAs which could predict response to ADT 106. Profiling different 
miRNAs in parallel makes sense, since many miRNAs are known to be involved in PCa development 
101, 103. It is also unlikely thatmiR-21 (or any other miRNA) as a single biomarker would be sufficient to 
accurately predict any given patient outcome. Therefore, the ability to measure expression levels of 
other miRNAs, or other genetic parameters, in combination with miR-21 should be built into the 
design of future studies investigating its prognostic value in cancer A multivariate profiling approach 
to PCa prognosis, which includes measurement of miR-21, would be a sensible approach to take.  
CONCLUSIONS: 
Meta-analyses of 11 studies in this report showed that high miR-21 expression was associated with 
poor prognosis in PCa. Qualitative summary of all 64 studies also found positive association of miR-
21 expression with various prognostic factors for PCa. These findings corroborate data from other 
systematic reviews which have shown similar findings for miR-21 in various cancers. However, 
further research is needed, including more high-quality investigations that follow standardised 
guidelines for study design. With continued effort, miR-21 could prove to be a clinically useful 
prognostic biomarker in prostate cancer.  
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FIGURE LEGENDS: 
Figure 1. Study flow diagram (Adapted from Moher et al. 23). 
 
Figure 2. Analysis 1.1: Meta-analysis of dichotomous miR-21 expression with recurrence-free 
survival (unadjusted). 
(a) Unadjusted results and forest plot, RevMan5.4 snapshot. (b) Sensitivity analysis of impact of outlier 
(Amankwah2013 31). 
BCR: Biochemical recurrence; CI: Confidence interval; HR: Hazard ratio; IV: Inverse variance; LCI: 
Lower confidence interval; SE: Standard error; UCI: Upper confidence interval 
 
Figure 3. Analysis 1.2: Meta-analysis of dichotomous miR-21 expression with recurrence-free 
survival (adjusted). 
(a) Adjusted results and forest plot, RevMan5.4 snapshot. (b) Sensitivity analysis of impact of outlier 
(Amankwah2013 31). 
BCR: Biochemical recurrence; CI: Confidence interval; HR: Hazard ratio; IV: Inverse variance; LCI: 
Lower confidence interval; SE: Standard error; UCI: Upper confidence interval 
 
Figure 4. Analysis 2: Meta-analysis of continuous miR-21 expression with recurrence-free survival. 
Unadjusted results and forest plot, RevMan5.4 snapshot. 
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Figure 5. Analysis 3: Meta-analysis of miR-21 expression with Overall Survival. 
(a) Unadjusted results and forest plot, RevMan5.4 snapshot. (b) Sensitivity analysis of impact of outlier 
(Sharova2021 78). 
CI: Confidence interval; HR: Hazard ratio; IV: Inverse variance; LCI: Lower confidence interval; SE: 
Standard error; UCI: Upper confidence interval 
 
Figure 6. Meta-analyses of miR-21 expression with progression-free survival. 
(a) Analysis 4.1: Unadjusted results and forest plot, RevMan5.4 snapshot. (b) Analysis 4.2: Adjusted 
results and forest plot, RevMan5.4 snapshot. 
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Table 1: PICOT eligibility criteria 
P Population Male patients of any age worldwide diagnosed with PCa. 
I Index prognostic 
factor 
Measurement of miR-21 levels in tissue or circulating/fluid samples such 
as tumour tissue, blood, plasma, serum, urine and seminal fluid. 
C Comparator 
prognostic factors 
Clinicopathological factors such as stage, grade, Gleason score, PSA level 
and health condition (e.g., recurrence, metastasis). 
O Outcomes of 
interest 
Survival outcomes of any type (e.g., OS, RFS) estimated in HR, 95% CI, p-
value and/or survival curves with log-rank p-value. 
T Timing Samples taken as baseline at the start of follow-up of any length. 
Studies with characteristics specified by PICOT were eligible for inclusion in meta-analysis. 
CI: Confidence interval; HR: Hazard ratio; OS: Overall survival; PCa: Prostate cancer; PSA: Prostate-specific 
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median age=57 (46-75) 
High/low miR-21, -221 
& -222 in FFPE tissue 
(TaqMan RT-qPCR) 




85 PCa pathologically confirmed; 
Underwent ADT a 
Mean age=75±7.7 
 
High/low levels of 7 
miRNAs (including miR-
21) in FFPE tissue 
(TaqMan RT-qPCR) 




127 Localised PCa; Underwent RP 
Mean age=63±7.6 
 
High/low miR-21 in 
FFPE tissue 
(TaqMan RT-qPCR) 




168 PCa pathologically confirmed; 
Underwent RP & regional 
lymph node dissection 
Low miR-21 median age=68 
(56-77) 
High miR-21 median age=67 
(48-77) 




invasion; GS; pN; 
PSA; pT; Surgical 
margin 




97 CRPC patients; Underwent 
docetaxel chemotherapy 
Median age=68 (46-87) 
High/low levels of 46 
miRNAs (including miR-










87 CRPC patients; Underwent 
docetaxel chemotherapy 
Median age=72 (40-89) 
High/low levels of 14 
miRNAs (including miR-











478 PCa patients; Underwent RP 
Median age=62 (45-75) 
High/low levels of 7 
miRNAs (including miR-
21-5p) in FFPE tissue 
(RT-qPCR) 
GG; Perineural 









31 mCRPC patients; Treated with 
ARTA b 
Median age=75 (69.5-80.5) 
High/low levels of miR-





cyte ratio; PSA; 








92 PCa pathologically confirmed; 
Underwent resection 
Mean age=60±6 
High/low miR-21 in 
PBMC 
(TaqMan RT-qPCR) 




49 Localised PCa; Underwent RP 
& regional lymph node 
dissection 
Mean age=62.7 (52-71) 
Continuous levels of 6 
miRNAs (including miR-
21) in FFPE tissue 
(ISH analysed by 
computer software) 




206 PCa patients; Underwent RP 
Median age=63 (47-74) 
Continuous levels of 20 
miRNAs (including miR-
21-5p) in FFPE tissue 
(TaqMan RT-qPCR) 
Age; DRE; PSA; ISUP 
grade c; pN; 
Prostate volume; 
pT; Surgical margin 
RFS f 17-180 
months 
ADT: Androgen deprivation therapy; ARTA: Androgen receptor-targeted agents; BMI: Body mass index; C: 
Comparator prognostic factors; CRPC: Castration-resistant prostate cancer; cT: Clinical tumour stage; DRE: 
Digital rectal examination; FFPE: Formalin-fixed paraffin-embedded; GG: Gleason grade; GS: Gleason score; I: 
Index prognostic factor; ISH: In situ hybridisation; ISUP: International Society of Urological Pathology; LNA-ISH: 
Locked nucleic acid in situ hybridisation; mCRPC: Metastatic castration-resistant prostate cancer; O: Outcomes 
of interest; OS: Overall survival; P: Population; PBMC: Peripheral blood mononuclear cell; PCa: Prostate 
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Pathological tumour stage; RFS: Recurrence-free survival; RP: Radical prostatectomy; RT-qPCR: Real-time 
quantitative polymerase chain reaction 
a ADT included surgical castration or luteinising hormone-releasing hormone agonist combined with an 
antiandrogen according to Guan2016 42. 
b ARTA included abiraterone (n=10) and enzalutamide (n=21) according to Sharova2021 78. 
c ISUP grading system was based on Gleason score according to Zhao2019a 89. 
d Endpoint included biochemical recurrence defined as serum PSA≥0.2ng/ml after treatment, clinical 
metastasis or PCa-specific death. 
e PFS defined as time to development of CRPC from initiation of ADT where progression to CRPC was defined 
as three consecutive monthly increases in serum PSA level against ADT according to Guan2016 42. 
f Biochemical recurrence defined as serum PSA≥0.2ng/ml after treatment. 
g Biochemical recurrence defined as serum PSA≥0.4ng/ml after treatment. 
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Table 3: Allocation of eleven studies into 4 meta-analyses 




Total no. of 
participants 
Study IDs Analysis 
RFS Dichotomous 4 838 Amankwah2013 31; Leite2015 60; 
Li2012 61; Melbø-Jørgensen2014 68 
1 
Continuous 2 255 Zedan2017 85; Zhao2019a 89 2 
OS Dichotomous 4 307 Lin2014 64; Lin2017 65; 
Sharova2021 78; Yang2016 84 
3 
PFS Dichotomous 2 116 Guan2016 42; Sharova2021 78 4 
Eleven eligible studies were allocated into four separate meta-analyses according to outcomes and handlings 
of miR-21 data. Note: Sharova2021 78 with two outcomes was allocated into Analyses 3 and 4. 








K user on 04 January 2022
Bioscience R
eports. This is an Accepted M
anuscript. You are encouraged to use the Version of R
ecord that, w
hen published, w
ill replace this version. The m
ost up-to-date-version is available at https://doi.org/10.1042/BSR
20211972
























Amankwah2013 31 HIGH LOW LOW LOW LOW LOW 
Guan2016 42 UNCLEAR LOW LOW LOW HIGH LOW 
Leite2015 60 UNCLEAR LOW LOW LOW LOW HIGH 
Li2012 61 UNCLEAR LOW MODERATE LOW LOW HIGH 
Lin2014 64 UNCLEAR LOW LOW LOW HIGH MODERATE 
Lin2017 65 UNCLEAR LOW LOW LOW HIGH MODERATE 
Melbø-Jørgensen2014 68 LOW LOW LOW LOW LOW MODERATE 
Sharova2021 78 MODERATE LOW LOW LOW HIGH LOW 
Yang2016 84 UNCLEAR MODERATE LOW LOW LOW UNCLEAR 
Zedan2017 85 MODERATE LOW MODERATE LOW UNCLEAR UNCLEAR 
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Table 5: Summary of results of individual studies eligible for meta-analysis 
Outcome 
(Analysis) 
Study ID Event 
/Total 
Univariate analysis: 
Unadjusted HR (95% CI) 
Multivariate analysis: 
Adjusted HR (95% CI) 
Covariates 









KM plot favouring high miR-21 
Estimated HR (95% CI) a: 
=4.83 (2.26-10.35), p=0.00005 
Inverse b: 













KM plot favouring low miR-21 
Estimated HR (95% CI) a: 










KM plot favouring low miR-21 
Estimated HR (95% CI) a: 

















(Cut-off=4th quartile; log-rank 
p=0.006) 
KM plot favouring low miR-21 
Estimated HR (95% CI) a: 
=1.65 (1.15-2.36), p=0.006 












Zedan2017 85 19/49 
(39%) 
(Continuous miR-21) 




Zhao2019a 89 98/206 
(48%) 
(Continuous miR-21) 









Lin2014 64 55/97 
(57%) 
(High vs low miR-21, cut-
off=median) 




Lin2017 65 53/87 
(61%) 















5.8 (1.0-33.1), p=0.049 
Inverse b: 
Haemoglobin 
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KM plot favouring high miR-21  
5.2 (1.7-15.7), p=0.0191 
Inverse b: 
=0.192 (0.064-0.588), p=0.0191 
=0.172 (0.03-1.0), 
p=0.049 
Yang2016 84 42/92 
(46%) 
(Cut-off not stated; log-rank 
p<0.05) 
KM plot favouring low miR-21 
Estimated HR (95% CI) a: 
















KM plot favouring low miR-21 








KM plot favouring high miR-21 
7.4 (2.6-21.2), p=0.0021 
 Inverse b: 
=0.135 (0.047-0.385), p=0.0021 





Time to CRPC 
*GS/GG and pT/cT were predefined as important prognostic factors that should be adjusted for in multivariate 
analysis. 
BCR: Biochemical recurrence; CI: Confidence interval; CRPC: Castration-resistant prostate cancer; cT: Clinical 
tumour stage; GG: Gleason grade; GS: Gleason score; HR: Hazard ratio; KM: Kaplan Meier; N/A: Not 
applicable; OS: Overall survival; PFS: Progression-free survival; pN: Lymph node metastasis; PSA: Prostate-
specific antigen; PSM: Positive surgical margins; pT: Pathological tumour stage; RFS: Recurrence-free survival 
a Unadjusted HR (95% CI) was not reported; hence it was estimated using an Excel calculator 94.  
b The direction of effect estimates in Amankwah2013 31 and Sharova2021 78 were opposite to the rest of 
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Table 6: Summary of association results of included studies 
Association result Gleason (n=28)
 
* Stage (n=18) PSA (n=18)
 
* 















U Samaan2014   
Neg T Ren2014 Ren2014  
p>0.05 Pos T Katz2014; Kurul2019; 
Lichner2015; Reis2012; 
Zedan2017; Zedan2018 
Zedan2017 Li2012; Reis2012; Zedan2018; 
Zhao2019a 
C Shen2012 Shen2012 
Zedan2019 




** Katz2014 Zedan2017 
C Kotb2014; Zedan2018; 
Zedan2019 
 Sharova2021; Yang2016; 
Zhao2019b 
No diff T Amankwah2013  Guan2016; Katz2014 





Pos T  Hart2014  
No corr C   Agaoglu2011 
 
Association result Recurrence (n=19) Metastasis (n=14) Risk (n=12) Age (n=9) 
P<0.05 Pos T Leite2015; Li2012; 
Melbø-Jørgensen2014; 
Reis2012 
Guan2016; Li2012 Zhu2019  
















Ren2014  Ren2014 
C  Danarto2020   
p>0.05 Pos T Kurul2019; Leite2011; 
Ren2014 
 Katz2014; Leite2013; 
Zedan2017 
 




Neg T Katz2014 Leite2011 Lichner2013 Zhao2019a; Li2012 







  Guan2016 
C Singh2014    
No 
p-value 
Pos T  Bonci2016   
Most of the 64 studies included in this review compared the association of miR-21 with commonly used 
clinicopathological prognostic factors (Gleason score/grade; pathological/clinical stage; serum PSA level; risk 
stratification; age at diagnosis), as well as recurrence and metastasis. 
Study IDs in bold were eligible for meta-analysis (n=11). 
Possible part overlap of participants between Ibrahim2019a 48 and Ibrahim2019b 49. 
* Zedan2018 86 was counted twice as both tissue and plasma miR-21 expressions were measured. 
** 3p strand of miR-21 was measured. 
C: Circulating miR-21; corr: Correlation; diff: Difference; Neg: Negative association; Pos: Positive association; 
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HR (95% CI) 
No. of 
participants 
Certainty rate-downs Overall 
certainty e 
1.1 RFS a, c 1.54 (1.23-1.92) 838 
(4 studies) 
- RoB: High RoB in 3 studies 
- Imprecision: Estimated HR in all 
studies 
LOW 
1.2 RFS b, c 1.58 (1.19-2.09) 838 
(4 studies) 
- RoB: High RoB in 3 studies MODERATE 
2 RFS a, d 1.12 (1.01-1.26) 255 
(2 studies) 
- RoB: Unadjusted HR & high 
RoB in 1 study 
- Imprecision: CI close to HR 1 
LOW 
3 OS a, c 1.46 (1.06-2.01) 307 
(4 studies) 
- RoB: Unadjusted HR & high 
RoB in 3 studies 
- Indirectness: Lin 2014 & Lin 
2017 recruited CRPC patients 
to address chemo-response 
- Imprecision: Estimated HR in 1 
study; CI close to HR 1 
VERY LOW 
4.1 PFS a, c 1.09 (0.63-1.88) 116 
(2 studies) 
- RoB: High RoB in both studies 
- Inconsistency: Opposite 
direction results 
- Imprecision: Wide CI crossing 
HR 1 
VERY LOW 
4.2 PFS b, c 1.26 (0.70-2.27) 116 
(2 studies) 
- RoB: High RoB in both studies 
- Inconsistency: Opposite 
direction results 
- Imprecision: Wide CI crossing 
HR 1 
VERY LOW 
CI: Confidence interval; CRPC: castration-resistant prostate cancer; HR: Hazard ratio; OS: Overall survival; RFS: Recurrence-
free survival; RoB: Risk of bias 
a Unadjusted effect estimates  
b Adjusted effect estimates  
c Dichotomised miR-21 levels 
d Continuous miR-21 levels 
e 
HIGH: We are very confident that the variation in risk associated with miR-21 expression lies close to that of the estimate; 
MODERATE: We are moderately confident that the variation in risk associated with miR-21 expression is likely to be close 
to the estimate, but substantial difference is possible; LOW: We have limited certainty in the estimate, the variation in risk 
associated with miR-21 expression may be substantially different from the estimate; VERY LOW: We have very little 
certainty in the estimate, the variation in risk associated with miR-21 expression is likely to be substantially different from 
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ST 1: Search strategies in electronic databases 
Medline (Ovid) 
1. exp MicroRNAs/  
2. (microRNA or miRNA or microRNA-21 or microRNA21 or miRNA-21 or miRNA21 or miR-21 or miR21)  
3. exp Prostatic Neoplasms/  
4. (prostat* cancer* or prostat* carcinoma* or prostat* tumo?r* or prostat* neoplasm* or prostat* adenocarcinoma* or PRAD)
  
5. exp Biomarkers/  
6. exp Prognosis/ 
7. exp Survival Analysis/  
8. (biomarker* or marker* or prognos* or survival)  
9. 1 or 2  
10. 3 or 4  
11. 5 or 6 or 7 or 8  
12. 9 and 10 and 11  
13. limit 12 to yr="2010 -Current"  
14. limit 13 to english language  
15. limit 14 to (case reports or editorial or english abstract or letter or meta analysis or "review" or "systematic review")  
16. 14 not 15  
EMBASE 
1. exp microRNA 21/  
2. exp microRNA/  
3. (microRNA or miRNA or microRNA-21 or microRNA21 or miRNA-21 or miRNA21 or miR-21 or miR21)  
4. 1 or 3  
5. exp prostate cancer/  
6. (prostat* cancer* or prostat* carcinoma* or prostat* tumo?r* or prostat* neoplasm* or prostat* adenocarcinoma* or PRAD)
  
7. 5 or 6  
8. exp prognosis/ 
9. exp biological marker/  
10. exp survival/ or exp survival analysis/  
11. (biomarker* or marker* or prognos* or survival)  
12. 8 or 9 or 10 or 11  
13. 4 and 7  
14. 12 and 13  
15. limit 14 to yr="2010 -Current"  
16. limit 15 to english language  
17. limit 16 to (meta analysis or "systematic review")  
18. limit 16 to (books or chapter or conference abstract or editorial or letter or "review" or short survey)  
19. 17 or 18  
20. 16 not 19 
Web of Science (Core Collection) 
1. TOPIC: ("microRNA-21" OR "microRNA21" OR "miRNA-21" OR "miRNA21" OR "miR-21" OR "miR21" OR microRNA OR miRNA) 
2. TOPIC: ("prostat* cancer*" or "prostat* carcinoma*" or "prostat* tumo?r*" or "prostat* neoplasm*" or "prostat* 
adenocarcinoma*" or PRAD) 
3. TOPIC: (biomarker* or marker* or prognos* or survival) 
4. #3 AND #2 AND #1 Refined by: [excluding] PUBLICATION YEARS: ( 2008 OR 2007 OR 2006 OR 2009 ) AND LANGUAGES: 
( ENGLISH ) AND [excluding] DOCUMENT TYPES: ( EDITORIAL MATERIAL OR LETTER OR REVIEW OR PROCEEDINGS PAPER OR 
RETRACTED PUBLICATION OR RETRACTION OR MEETING ABSTRACT OR BOOK CHAPTER ) 
Scopus 
( TITLE-ABS-KEY ( biomarker*  OR  marker*  OR  prognos*  OR  survival ) )  AND  ( ( TITLE-ABS-KEY ( "microRNA-21"  OR  
"microRNA21"  OR  "miRNA-21"  OR  "miRNA21"  OR  "miR-21"  OR  "miR21"  OR  "circulating microRNA*" ) )  AND  ( TITLE-ABS-
KEY ( "prostat* cancer*"  OR  "prostat* carcinoma*"  OR  "prostat* tumo?r*"  OR  "prostat* neoplasm*"  OR  "prostat* 
adenocarcinoma*"  OR  prad ) ) )  AND  ( EXCLUDE ( PUBYEAR ,  2009 )  OR  EXCLUDE ( PUBYEAR ,  2008 ) )  AND  ( LIMIT-TO 
( LANGUAGE ,  "English" ) )  AND  ( EXCLUDE ( DOCTYPE ,  "ch" )  OR  EXCLUDE ( DOCTYPE ,  "ed" )  OR  EXCLUDE ( DOCTYPE ,  "sh" )  
OR  EXCLUDE ( DOCTYPE ,  "no" ) )  AND  ( LIMIT-TO ( DOCTYPE ,  "ar" ) ) 
Cochrane Library 
microRNA-21 or microRNA21 or miRNA-21 or miRNA21 or miR-21 or miR21 or microRNA or miRNA or miR in All Text AND prostate 
or prostatic in Title Abstract Keyword AND cancer or carcinoma or tumour or tumor or neoplasm or adenocarcinoma or PRAD in 
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ST 2: Data items included in Covidence data extraction form (Adapted from CHARMS-PF checklist 22) 
General information 
Study ID  
Title  
Lead author and contact details 
Country in which the study conducted 
Study funding sources 
Possible conflicts of interest for study authors 
Notes 
Source of data 
Source of data (e.g., cohort, case control, randomised trial or registry data) 
Participants 
Participant eligibility and recruitment method 
Participant description 
Details of treatments received (if relevant) 
Study dates 
Outcomes to be predicted 
Definition and method for measurement of outcomes 
Was the same outcome definition (and method for measurement) used in all participants? 
Types of outcomes 
Were the outcomes assessed without knowledge of the candidate prognostic factors (i.e., blinded)? 
Were candidate prognostic factors part of the outcome? 
Time of outcome occurrence or summary of duration of follow-up 
Prognostic factors (index and comparator) 
Number and type of prognostic factors 
Definition and method for measurement of prognostic factors 
Timing of prognostic factor measurement 
Were prognostic factors assessed blinded for outcome, and for each other (if relevant)? 
Handling of prognostic factors in the analysis 
Sample size 
Was a sample size calculation conducted and, if so, how? 
Number of participants and number of outcomes or events 
Number of outcomes or events in relation to the number of candidate prognostic factors (events per variable) 
Missing data 
Number of participants with any missing value 
Number of participants with missing data for miR-21 expression 
Details of attrition (loss to follow-up) and, for time-to-event outcomes, number of censored observations 
Handling of missing data 
Analysis (N/A for studies excluded from meta-analysis) 
Modelling method 
How modelling assumptions were checked; the method for assessing non-proportional hazards  
Method for selection of prognostic factors for inclusion in multivariable modelling 
Method for selection or exclusion of prognostic factors during multivariable modelling, and criteria used for any 
selection or exclusion 
Method of handling each continuous prognostic factor, including values of any cut points used and their justification 
Results of studies included in meta-analysis 
Unadjusted and adjusted prognostic effect estimates for miR-21 expression, the corresponding 95% confidence interval 
with p-value. 
For the extracted adjusted prognostic effect estimate of interest, the set of adjustment factors used 
Results of studies excluded from meta-analysis 
Prognostic factors or stratification used for association analysis 
Type of association analysis and estimates with p-value 
Interpretation and discussion 
Interpretation of presented results 
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ST 3: Records of authors contacted (12 studies) 
Study ID Author contacted Response Additional data 




Yes miR-21 raw data excel file including 
78 PCa patients 
Fendler2011 40 Klaus Jung 
<klaus.jung@charite.de> 
Yes No (Communication stopped 
without useful data) 
Huang2015a 46 Liang Wang 
<liwang@mcw.edu> 
No  
Kelly2015 52 Brian Kelly 
<drbriankelly@hotmail.com> 
Yes No (Communication stopped 
without useful data) 
Leite2013 59 Katia Ramos Moreira Leite 
Updated: <katiaramos@usp.br> 
Yes Clarification on results reported 
Leite2015 60 Details of multivariate analysis 
Lin2014 64 Hui-Ming Lin 
<h.lin@garvan.org.au> 
Yes Clarification on analysis method 
Lin2017 65 Results of univariate & multivariate 
analyses 
McDonald2019 67 Alicia McDonald 
<amcdonald3@phs.psu.edu> 
Yes No (miR-21 measured but not 
analysed because it did not meet 
criteria) 
Mortensen2014 69 Lars Dyrskjøt Andersen 
<lars@clin.au.dk> 
Yes Raw unanalysed data 
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ST 4: QUIPS (Quality in Prognostic Factor Studies) risk of bias classification tool 26 
 QUIPS domains 
Signalling 
items 
1. Study participation 
(a) Adequate participation in the study by eligible persons 
(b) Description of the target population or population of interest 
(c) Description of the baseline study sample 
(d) Adequate description of the sampling frame and recruitment 
(e) Adequate description of the period and place of recruitment 
(f) Adequate description of inclusion and exclusion criteria 
Risk of bias 
ratings * 
HIGH MODERATE LOW 
The relationship between the PF and 
outcome is very likely to be different 
for participants and eligible non-
participants 
The relationship between the PF and 
outcome may be different for 
participants and eligible non-
participants 
The relationship between the PF and 
outcome is unlikely to be different 




2. Study attrition 
(a) Adequate response rate for study participants 
(b) Description of attempts to collect information on participants who dropped out 
(c) Reasons for loss to follow-up are provided 
(d) Adequate description of participants lost to follow-up 
(e) There are no important differences between participants who completed the study and those who did not 
Risk of bias 
ratings * 
HIGH MODERATE LOW 
The relationship between the PF and 
outcome is very likely to be different 
for completing and non-completing 
participants 
The relationship between the PF and 
outcome may be different for 
completing and non-completing 
participants 
The relationship between the PF and 
outcome is unlikely to be different 




3. Prognostic factor measurement 
(a) A clear definition or description of the PF is provided 
(b) Method of PF measurement is adequately valid and reliable 
(c) Continuous variables are reported or appropriate cut-points are used 
(d) The method and setting of measurement of PF is the same for all study participants 
(e) Adequate proportion of the study sample has complete data for the PF 
(f) Appropriate methods of imputation are used for missing PF data 
Risk of bias 
ratings * 
HIGH MODERATE LOW 
The measurement of the PF is very 
likely to be different for different 
levels of the outcome of interest 
The measurement of the PF may be 
different for different levels of the 
outcome of interest 
The measurement of the PF is 
unlikely to be different for different 
levels of the outcome of interest 
Signalling 
items 
4. Outcome measurement 
(a) A clear definition of the outcome is provided 
(b) Method of outcome measurement used is adequately valid and reliable 
(c) The method and setting of outcome measurement is the same for all study participants 
Risk of bias 
ratings * 
HIGH MODERATE LOW 
The measurement of the outcome is 
very likely to be different related to 
the baseline level of the PF 
The measurement of the outcome 
may be different related to the 
baseline level of the PF 
The measurement of the outcome is 
unlikely to be different related to 
the baseline level of the PF 
Signalling 
items 
5. Adjustment for covariates 
(a) All other important covariates are measured 
(b) Clear definitions of the important covariates measured are provided 
(c) Measurement of all important covariates is adequately valid and reliable 
(d) The method and setting of covariate measurement are the same for all study participants 
(e) Appropriate methods are used to deal with missing values of covariates, such as multiple imputation 
(f) Important covariates are accounted for in the study design 
(g) Important covariates are accounted for in the analysis 
Risk of bias 
ratings * 
HIGH MODERATE LOW 
The observed effect of the covariate 
on the outcome is very likely to be 
distorted by another factor related 
to PF and outcome 
The observed effect of the covariate 
on outcome may be distorted by 
another factor related to PF and 
outcome 
The observed effect of the covariate 
on outcome is unlikely to be 
distorted by another factor related 
to PF and outcome 
Signalling 
items 
6. Statistical analysis and reporting 
(a) Sufficient presentation of data to assess the adequacy of the analytic strategy 
(b) Strategy for model building is appropriate and is based on a conceptual framework or model 
(c) The selected statistical model is adequate for the design of the study 
(d) There is no selective reporting of results 
Risk of bias 
ratings * 
HIGH MODERATE LOW 
The reported results are very likely 
to be spurious or biased related to 
analysis or reporting 
The reported results may be 
spurious or biased related to analysis 
or reporting 
The reported results are unlikely to 
be spurious or biased related to 
analysis or reporting 
* Risk of bias is rated as Unclear when there is insufficient information to inform judgment. 
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ST 5: Reasons for exclusion of 13 full-text articles 
Reason for exclusion Full-text articles 
No prognostic data 
(n=8) 
Benoist2020; Egidi2013; Li2015; Liu2018; Martens-Uzunova2012; Osipov2016; 
Valera2020; Yang2015 
miR-21 not studied 
(n=4) 







Benoist, G.E., van Oort, I.M., Boerrigter, E., Verhaegh, G.W., van Hooij, O., Groen, L., Smit, F., de Mol, P., Hamberg, P., Dezentjé, 
V.O. and Mehra, N., 2020. Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate 
Cancer Treated with Enzalutamide: A Prospective Observational Study. Clinical Chemistry, 66(6), pp.842-851. 
Egidi2013 
Egidi, M.G., Cochetti, G., Serva, M.R., Guelfi, G., Zampini, D., Mechelli, L. and Mearini, E., 2013. Circulating microRNAs and 
kallikreins before and after radical prostatectomy: are they really prostate cancer markers?. BioMed research 
international, 2013. 
Haldrup2014 
Haldrup, C., Kosaka, N., Ochiya, T., Borre, M., Høyer, S., Orntoft, T.F. and Sorensen, K.D., 2014. Profiling of circulating microRNAs 
for prostate cancer biomarker discovery. Drug delivery and translational research, 4(1), pp.19-30. 
Knyazev2016 
Knyazev, E., Samatov, T., Fomicheva, K., Nyushko, K., Alekseev, B. and Shkurnikov, M., 2016. MicroRNA hsa-miR-4674 in 
hemolysis-free blood plasma is associated with distant metastases of prostatic cancer. Bulletin of Experimental Biology & 
Medicine, 161(1). 
Kumar2018 
Kumar, B., Rosenberg, A.Z., Choi, S.M., Fox-Talbot, K., De Marzo, A.M., Nonn, L., Brennen, W.N., Marchionni, L., Halushka, M.K. 
and Lupold, S.E., 2018. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and 
prostate cancer. Scientific reports, 8(1), pp.1-13. 
Li2015 
Li, M., Rai, A.J., DeCastro, G.J., Zeringer, E., Barta, T., Magdaleno, S., Setterquist, R. and Vlassov, A.V., 2015. An optimized 
procedure for exosome isolation and analysis using serum samples: application to cancer biomarker discovery. Methods, 87, 
pp.26-30. 
Liu2018 
Liu, R.S., Olkhov-Mitsel, E., Jeyapala, R., Zhao, F., Commisso, K., Klotz, L., Loblaw, A., Liu, S.K., Vesprini, D., Fleshner, N.E. and 
Bapat, B., 2018. Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active 
surveillance. The Journal of urology, 199(6), pp.1475-1481. 
Martens-Uzunova2012 
Martens-Uzunova, E.S., Jalava, S.E., Dits, N.F., Van Leenders, G.J.L.H., Møller, S., Trapman, J., Bangma, C.H., Litman, T., Visakorpi, 
T. and Jenster, G., 2012. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate 
cancer. Oncogene, 31(8), pp.978-991. 
Moltzahn2011 
Moltzahn, F., Olshen, A.B., Baehner, L., Peek, A., Fong, L., Stöppler, H., Simko, J., Hilton, J.F., Carroll, P. and Blelloch, R., 2011. 
Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer 
patients. Cancer research, 71(2), pp.550-560. 
Nam2015 
Nam, R.K., Amemiya, Y., Benatar, T., Wallis, C.J., Stojcic-Bendavid, J., Bacopulos, S., Sherman, C., Sugar, L., Naeim, M., Yang, W. 
and Zhang, A., 2015. Identification and validation of a five microRNA signature predictive of prostate cancer recurrence and 
metastasis: a cohort study. Journal of Cancer, 6(11), p.1160. 
Osipov2016 
Osipov, I.D., Zaporozhchenko, I.A., Bondar, A.A., Zaripov, M.M., Voytsitskiy, V.E., Vlassov, V.V., Laktionov, P.P. and Morozkin, E.S., 
2016. Cell-free miRNA-141 and miRNA-205 as prostate cancer biomarkers. In Circulating Nucleic Acids in Serum and Plasma–
CNAPS IX (pp. 9-12). Springer, Cham. 
Valera2020 
Valera, V.A., Parra-Medina, R., Walter, B.A., Pinto, P. and Merino, M.J., 2020. microRNA expression profiling in young prostate 
cancer patients. Journal of Cancer, 11(14), p.4106. 
Yang2015 
Yang, C.H., Pfeffer, S.R., Sims, M., Yue, J., Wang, Y., Linga, V.G., Paulus, E., Davidoff, A.M. and Pfeffer, L.M., 2015. The oncogenic 
microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis. Journal of Biological 
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ST 6: Characteristics of included studies and references (n=64) 
Ref 
no. 





29 Agaoglu2011 51 plasma Not specified PSA, metastasis Correlation, 
median diff 
30 Al-Qatati2017 79 plasma miR-21-5p GS, pT, PSA, risk groups FC 
31 Amankwah 
2013 
65 tissue Not specified Aggressiveness (determined 




32 Arisan2020 40 tissue Not specified GS % diff 
33 Bell2015 * 43 tissue Not specified (Raw data of m-R-21 in GEO not analysed. No 
other miR-21 data available.) 
34 Bonci2016 15 tissue Not specified Metastasis % diff 
35 Brase2011 21 serum Not specified Metastasis FC 
36 Bryant2012 * 78 plasma Not specified (Author provided miR-21 raw data excel file.) 
 
37 Danarto2020 60 urine 
exosome 
miR-21-5p Metastasis Mean diff 
38 Endzeliņš 
2017 * 
50 plasma or 
exosome 
miR-21-5p (Comparison and ROC curve of miR-21 
expression between GS≥8 & ≤6 were done but 
not shown due to insignificant result.) 
39 Farran2018 114 plasma Not specified Aggressiveness (determined 
by GS) 
OR 
40 Fendler2011 * 52 tissue Not specified (Communication with authors failed to obtain 
full list of differentially expressed miRNAs.) 
41 Foj2017 60 urine, 
urine 
exosome 
miR-21-5p GS, D'Amico risk groups Mean diff 
42 Guan2016 85 tissue Not specified GS, PSA, metastasis, age Correlation 
43 Gurbuz2020 65 whole 
blood 
Not specified GS, TNM, PSA FC diff 
44 Hart2014 20 tissue Not specified pT FC diff 
45 Hoey2019 75 serum miR-21-5p Risk groups FC 






miR-21-5p (miR-21 raw data in supplemental materials; 
overall survival might have been analysed but 
contact author failed.) 
47 Huang2015b 75 PBMC Not specified pT, cT, pN, metastasis, 
recurrence, age 
Mean diff 




49 Ibrahim2019b 80 plasma Not specified GS, pT, PSA, metastasis, DRE, 
prostate volume 
Median diff 
50 Ju2019 88 serum Not specified GS, pT, PSA, metastasis, BCR, 
risk groups 
Mean diff 
51 Katz2014 51 tissue Not specified GS, pT, PSA, BCR, risk groups Mean diff 
52 Kelly2015 * 75 whole 
blood 
Not specified (miR-21 was among the 12 selected for 
expression profiling, but data wasn't 
presented. Author stopped communication.) 
53 Kopcalic2019 15 PBMC Not specified Acute genitourinary 
radiotoxicity 
Mean diff 
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56 Kurul2019 45 tissue Not specified Gleason upgrade, BCR FC diff 
57 Leite2011a 22 tissue Not specified Metastasis Mean diff 
58 Leite2011b 49 tissue Not specified BCR Mean diff 
59 Leite2013 ** 48 tissue Not specified Risk groups (favourable vs 
non-favourable) 
Mean diff 






BCR FC, mean 
diff 
61 Li2012 168 tissue Not specified GS, pT, PSA, pN, BCR, age, 
surgical margin, capsular 
invasion, organ confined 
disease 
% diff 






Risk groups FC 







64 Lin2014 * 97 plasma or 
serum 
Not specified (Pre-docetaxel median diff and post-docetaxel 
median FC in responder vs non-responder 
compared. Results for miR-21 not shown due 
to insignificant p-values.) 
65 Lin2017 * 87 plasma Not specified (No association analysis with comparator.) 
 




tissue Not specified (miR-21 expression relating to BCR prediction 




66 plasma Not specified (miR-21 expression measured but not 












36 tissue Not specified (miR-21 expression measured but not 
analysed.) 
 
70 Nam2018 * 38 tissue miR-21-5p, 
miR-21-3p 
(miR-21 normalised read count available in 
GEO, not analysed.) 
71 Ostano2020 48 tissue miR-21-3p Neuroendocrine-like vs Adeno 
PCa 
FC 
72 Reis2012 53 tissue Not specified GS, pT, PSA, BCR Mean diff 
73 Ren2014 204 tissue Not specified GS, pT, metastasis, BCR, age, 




74 Samaan2014 95 Not stated Not specified GG FC 
75 Sapre2014 36 urine Not specified Risk groups Ct FC 
76 Schubert  
2013 * 
13 tissue Not specified (miR-21 tested in microarray; raw data 
deposited in GEO (GSE18671); not included in 
further tests because of insignificant 
differential expression in high-risk PCa 
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serum Not specified BCR FC 
78 Sharova2021 31 plasma miR-21-5p Haemoglobin; 
Neutrophil/lymphocyte ratio; 
PSA; Time to CRPC 
Correlation 
79 Shen2012 82 plasma Not specified GS, pT, PSA, BCR, risk groups 
(CAPRA, D'Amico), age, 
prostate volume, ethnicity, 









143 urine Not specified GS, pT, BCR FC 
82 Suer2019 40 tissue miR-21-3p BCR FC 
83 Watahiki2013 50 plasma Not specified mCRPC Mean diff 
84 Yang2016 92 PBMC Not specified GS, cT, PSA, metastasis 
(bone), BCR, age 
Mean diff 
85 Zedan2017 49 tissue Not specified GS, pT, PSA, risk groups 
(D'Amico, NCCN) 
Correlation 






Not specified GS, PSA  Mean diff 
87 Zedan2019 149 plasma Not specified GS, cT, PSA, risk groups (EAU), 
age, prostate volume 
Correlation 
88 Zhang2011 50 serum Not specified Chemo-resistance  
89 Zhao2019a 206 tissue miR-21-5p ISUP (based on GS), pT, PSA, 
age, DRE, margin 
Correlation 
90 Zhao2019b 103 urine Not specified PSA, age, %core, 
reclassification 
Correlation 





92 Zhu2019 158 tissue Not specified Risk groups (identified by 
GAS5 SNPs) 
FC 
Studies in bold are eligible for meta-analyses (n=11). 
Possible part overlap of participants between Ibrahim2019a 48 and Ibrahim2019b 49. 
* miR-21 expression measured but no useful data for narrative summary (n=13). 
** (Leite2013 59) A corrigendum would be published in Urologic Oncology. 
ARTA: Androgen receptor-targeted agents; BCR: Biochemical recurrence; BPH: Benign prostate enlargement; 
CAPRA: Cancer of the Prostate Risk Assessment; CRPC: Castration-resistant prostate cancer; cT: Clinical 
tumour stage; Ct: Threshold cycle; diff: Difference; DRE: Digital rectal examination; EAU: European Association 
of Urology; FC: Fold change; GAS5: Growth Arrest Specific 5; GEO: Gene Expression Omnibus; GG: Gleason 
grade; GS: Gleason score; ISUP: International Society of Urological Pathology; mCRPC: Metastatic castration 
resistant prostate cancer; miRNAs: microRNAs; NCCN: National Comprehensive Cancer Network; OR: Odds 
ratio; PBMC: Peripheral blood mononuclear cell; PCa: Prostate cancer; pN: Lymph node metastasis; PSA: 
Prostate-specific antigen; pT: Pathological tumour stage; ROC: Receiver operating characteristic; SNPs: Single-
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Agaoglu2011 
Agaoglu, F.Y., Kovancilar, M., Dizdar, Y., Darendeliler, E., Holdenrieder, S., Dalay, N. and Gezer, U., 2011. Investigation of miR-
21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biology, 32(3), pp.583-588. 
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ST 7: Rationales for rating down certainty of evidence - GRADE 
Domains Analysis 1.1 Analysis 1.2 Analysis 2 Analysis 3 Analysis 4.1 Analysis 4.2 
RoB Estimate was unadjusted 
but sensitivity analysis 
showed limited 
difference in HR, rate-
down not necessary. 
 
High RoB in 3 studies 
(Amankwah2013 – 
Domain 1, Leite2015 & 
Li2012 – Domain 6), rate 
down 1 point. 
Visual inspection of the 
point estimates and CI 
showed limited 
difference caused by 




High RoB in 3 studies 
(Amankwah2013 – 
Domain 1, Leite2015 & 
Li2012 – Domain 6), rate 
down 1 point. 
Unadjusted estimate and 
high RoB in 1 study 
(Zhao2019a – Domain 5), 
rate down 1 point. 
Unadjusted estimate and 
high RoB in 3 studies 
(Lin2014, Lin2017 & 
Sharova2021 – Domain 
5), rate down 1 point. 
High RoB in both studies 
(Domain 5), rate down 1 
point. 
High RoB in both studies 
(Domain 5), rate down 1 
point. 
Inconsistency Amankwah2013 outlying 
but low weight (8.5%), 
rate-down not necessary. 
Amankwah2013 outlying 
but low weight (8.5%), 
rate-down not necessary. 
Both studies showed 
positive association and 
CI overlapped, no rate-
down. 
Sharova2021 outlying but 
low weight (8.2%), rate-
down not necessary. 
The two studies showed 
opposite direction 
results, rate down 1 
point. 
The two studies showed 
opposite direction 
results, rate down 1 
point. 
Indirectness Amankwah2013 RFS 
endpoint included clinical 
metastasis and PCa death 
but low weight, rate-
down not necessary. 
Amankwah2013 RFS 
endpoint included clinical 
metastasis and PCa death 
but low weight, rate-
down not necessary. 
No rate-down.  Lin2014 & Lin2017 
included CRPC patients, 
not representing entire 
PCa population; main aim 
was to address chemo-
response, rate down 1 
point. 
No rate-down. No rate-down. 
Imprecision Pooled CI well excluded 
HR of 1 but individual 
HRs were not reported 
and hence estimated 
from available data, rate 
down 1 point. 
Pooled CI well excluded 
HR of 1, no rate-down. 
Pooled CI close to HR of 1 
(CI: 1.01-1.26), rate down 
1 point. 
HR was not reported and 
hence estimated from 
available data in Yang 
2016. Pooled CI close to 
HR of 1 (CI: 1.06-2.01), 
rate down 1 point. 
Wide pooled CI crossing 
HR of 1 (CI: 0.63-1.88), 
rate down 1 point. 
Wide pooled CI crossing 
HR of 1 (CI: 0.70-2.27), 
rate down 1 point. 
Publication bias Publication bias was not assessed because there was inadequate number of studies for proper assessment by funnel plot and statistical tests. 
Overall 
certainty 
LOW MODERATE LOW VERY LOW VERY LOW VERY LOW 
CI: Confidence interval; CRPC: Castration-resistant prostate cancer; HR: Hazard ratio; mCRPC: metastatic castration-resistant prostate cancer; PCa: Prostate cancer; RFS: 







K user on 04 January 2022
Bioscience R
eports. This is an Accepted M
anuscript. You are encouraged to use the Version of R
ecord that, w
hen published, w
ill replace this version. The m




SF 1: Associations of miR-21 expression with clinicopathological measurements. (a) Gleason 
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PRISMA 2009 Checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
5-6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
5, ST1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
5 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
6, ST3 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
6, ST2 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
6-7, ST4 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
7 
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Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
7 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
7 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
8 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
8-9, Table 
2 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  10, Table 4 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
10, Table 5 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  10-13 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  15, Table 7 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  11-13 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
16 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
16-20 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  20 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
1, 21 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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